SAN DIEGO, May 19 /PRNewswire/ -- Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene’s president and CEO, will discuss the mechanism, antitumor properties and tumor selectivity of CX-4945, the Company’s oral protein kinase inhibitor currently in Phase I clinical trials. This proprietary compound has demonstrated promise as a potent and selective oral inhibitor of protein kinase CK2, a previously unexploited molecular target with well documented roles in many cancers, indicating broad therapeutic potential. Cylene’s Serine/Threonine Kinase Inhibitor program has also delivered orally active pan-PIM inhibitors of the PIM-1,2,3 kinases, still in pre-clinical development.
Cylene Pharmaceuticals, Inc. is a Phase II-stage, small-molecule Oncology Company designing promising therapeutic agents with its two proprietary product discovery platforms, using novel chemistry and biology capabilities. The company was co-founded by Daniel Von Hoff, MD, one of the world’s leading oncology clinical investigators. In addition to the CK2 inhibitor CX-4945, Cylene’s Nucleolus Targeting Technology has generated Quarfloxin (CX-3543), a small molecule agent that is in Phase II development for the treatment of carcinoid/neuroendocrine tumors (C/NET). Quarfloxin disrupts an essential protein: DNA complex in cancer cells, thereby knocking out a critical source of support for tumor cells and selectively causing cancer cell death. Quarfloxin is safe and well-tolerated and has completed two separate Phase I trials on different dosing schedules, during which biological activity was observed in several C/NET patients. More information can be found at www.cylenepharma.com.
CONTACT: Company, William Rice, Ph.D., President and CEO of Cylene
Pharmaceuticals, +1-858-875-5100, wrice@cylenepharma.com; or Media, Karen
Sparks of Mentus, +1-858-455-5500, ext. 275, karen@mentus.com, for Cylene
Pharmaceuticals
Web site: http://www.cylenepharma.com/
